Meritage Group’s Quest Diagnostics DGX Stock Holding History

Meritage Group’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-18,747	Closed	-$1.72M	–	39
2016 Q4	$1.72M	Buy	+18,747	New	+$1.62M	0.05%	48

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Meritage Group's DGX Position: Q1 2017 in Review

Meritage Group sold out of Quest Diagnostics (DGX) in Q1 2017, closing a stake of 18,747 shares — an estimated $1.72M sold.

Meritage Group first reported a position in DGX in Q4 2016 and held it in 1 quarter. The position peaked at $1.72M in Q4 2016. 614 funds tracked by Wall St. Rank hold DGX as of Q1 2017.

Meritage Group reported no remaining Quest Diagnostics position as of Q1 2017 after selling out during the quarter.
Meritage Group sold 18,747 Quest Diagnostics shares in Q1 2017, an estimated $1.72M.
Meritage Group first reported a position in Quest Diagnostics in Q4 2016 and held it in 1 quarter.
Meritage Group's Quest Diagnostics position peaked at $1.72M in Q4 2016.
614 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2017.

Based on Meritage Group's 13F filing for Q1 2017, filed 12 May 2017.